These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 11315840

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of glimepiride and glibenclamide on carotid atherosclerosis in type 2 diabetic patients.
    Katakami N, Kaneto H, Matsuhisa M, Shimomura I, Yamasaki Y.
    Diabetes Res Clin Pract; 2011 Apr; 92(1):e20-2. PubMed ID: 21257219
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE, Matthews DR.
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [Abstract] [Full Text] [Related]

  • 8. Vascular K(ATP) channel blockade by glibenclamide, but not by acarbose, in patients with Type II diabetes.
    Abbink EJ, Pickkers P, van Rosendaal AJ, Lutterman JA, Tack CJ, Russel FG, Smits P.
    Clin Sci (Lond); 2002 Mar; 102(3):307-14. PubMed ID: 11869171
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study.
    Shimabukuro M, Higa N, Takasu N.
    J Diabetes Complications; 2006 Mar; 20(3):179-83. PubMed ID: 16632238
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study.
    Dhindsa P, Davis KR, Donnelly R.
    Br J Clin Pharmacol; 2003 Jun; 55(6):616-9. PubMed ID: 12814458
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of glimepiride in Japanese type 2 diabetic subjects.
    Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M, Kashiwabara H, Yokota K, Suzuki M, Kurihara S, Awata T, Katayama S.
    Diabetes Res Clin Pract; 2005 Jun; 68(3):250-7. PubMed ID: 15936468
    [Abstract] [Full Text] [Related]

  • 19. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits.
    Nieszner E, Posa I, Kocsis E, Pogátsa G, Préda I, Koltai MZ.
    Exp Clin Endocrinol Diabetes; 2002 Aug; 110(5):212-8. PubMed ID: 12148084
    [Abstract] [Full Text] [Related]

  • 20. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Nutter B, Jain A, Atreja A, Zimmerman RS.
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.